Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies

Kidney International - Tập 73 Số 9 - Trang 994-1007 - 2008
Navjotsingh Pabla1, Zheng Dong1
1Department of Cellular Biology and Anatomy, Medical College of Georgia and Charlie Norwood VA Medical Center, Augusta, Georgia, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Rosenberg, 1965, Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode, Nature, 205, 698, 10.1038/205698a0

Wang, 2005, Cellular processing of platinum anticancer drugs, Nat Rev Drug Discov, 4, 307, 10.1038/nrd1691

Cohen, 2001, Cisplatin: from DNA damage to cancer chemotherapy, Prog Nucleic Acid Res Mol Biol, 67, 93, 10.1016/S0079-6603(01)67026-0

Arany, 2003, Cisplatin nephrotoxicity, Semin Nephrol, 23, 460, 10.1016/S0270-9295(03)00089-5

Siddik, 2003, Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene, 22, 7265, 10.1038/sj.onc.1206933

Ciccarelli, 1985, In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication, Biochemistry, 24, 7533, 10.1021/bi00347a005

Heiger-Bernays, 1990, Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication, Biochemistry, 29, 8461, 10.1021/bi00488a037

Zamble, 1995, Cisplatin and DNA repair in cancer chemotherapy, Trends Biochem Sci, 20, 435, 10.1016/S0968-0004(00)89095-7

Jamieson, 1999, Structure, recognition, and processing of cisplatin-DNA adducts, Chem Rev, 99, 2467, 10.1021/cr980421n

Eastman, 1987, The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes, Pharmacol Ther, 34, 155, 10.1016/0163-7258(87)90009-X

Kartalou, 2001, Mechanisms of resistance to cisplatin, Mutat Res, 478, 23, 10.1016/S0027-5107(01)00141-5

Wernyj, 2004, Molecular mechanisms of platinum resistance: still searching for the Achilles' heel, Drug Resist Updat, 7, 227, 10.1016/j.drup.2004.08.002

Siddik, 2002, Biochemical and molecular mechanisms of cisplatin resistance, Cancer Treat Res, 112, 263, 10.1007/978-1-4615-1173-1_13

Pasetto, 2006, The development of platinum compounds and their possible combination, Crit Rev Oncol Hematol, 60, 59, 10.1016/j.critrevonc.2006.02.003

Cornelison, 1993, Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin, Gynecol Oncol, 50, 147, 10.1006/gyno.1993.1184

Bajorin, 1986, Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline, Cancer Res, 46, 5969

Hill, 1982, Organo-platinum complexes as antitumor agents (review), Anticancer Res, 2, 173

Beyer, 1997, Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome, Bone Marrow Transplant, 20, 813, 10.1038/sj.bmt.1700980

Gonzales-Vitale, 1977, The renal pathology in clinical trials of cis-platinum (II) diamminedichloride, Cancer, 39, 1362, 10.1002/1097-0142(197704)39:4<1362::AID-CNCR2820390403>3.0.CO;2-N

Gomez Campdera, 1986, Cisplatin nephrotoxicity: symptomatic hypomagnesemia and renal failure, Int J Pediatr Nephrol, 7, 151

Brillet, 1994, Long-term renal effect of cisplatin in man, Am J Nephrol, 14, 81, 10.1159/000168693

Gately, 1993, Cellular accumulation of the anticancer agent cisplatin: a review, Br J Cancer, 67, 1171, 10.1038/bjc.1993.221

Ishida, 2002, Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals, Proc Natl Acad Sci USA, 99, 14298, 10.1073/pnas.162491399

Kuo, 2007, The roles of copper transporters in cisplatin resistance, Cancer Metastasis Rev, 26, 71, 10.1007/s10555-007-9045-3

Safaei, 2005, Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs, Crit Rev Oncol Hematol, 53, 13, 10.1016/j.critrevonc.2004.09.007

Kuo, 2006, Copper transport protein (Ctr1) levels in mice are tissue specific and dependent on copper status, J Nutr, 136, 21, 10.1093/jn/136.1.21

Ludwig, 2004, Nephrotoxicity of platinum complexes is related to basolateral organic cation transport, Kidney Int, 66, 196, 10.1111/j.1523-1755.2004.00720.x

Yonezawa, 2005, Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat, Biochem Pharmacol, 70, 1823, 10.1016/j.bcp.2005.09.020

Motohashi, 2002, Gene expression levels and immunolocalization of organic ion transporters in the human kidney, J Am Soc Nephrol, 13, 866, 10.1681/ASN.V134866

Ciarimboli, 2005, Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2, Am J Pathol, 167, 1477, 10.1016/S0002-9440(10)61234-5

Townsend, 2003, Metabolism of cisplatin to a nephrotoxin in proximal tubule cells, J Am Soc Nephrol, 14, 1, 10.1097/01.ASN.0000042803.28024.92

Hanigan, 1994, Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity, Cancer Res, 54, 5925

Hanigan, 2001, Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin, Am J Pathol, 159, 1889, 10.1016/S0002-9440(10)63035-0

Hanigan, 1999, Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo, Carcinogenesis, 20, 553, 10.1093/carcin/20.4.553

Lieberthal, 1996, Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis, Am J Physiol, 270, F700

Megyesi, 1998, Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure, J Clin Invest, 101, 777, 10.1172/JCI1497

Ramesh, 2003, TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure, Am J Physiol Renal Physiol, 285, F610, 10.1152/ajprenal.00101.2003

Liu, 2003, Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis, Kidney Int, 63, 1687, 10.1046/j.1523-1755.2003.00908.x

Faubel, 2004, Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis, Kidney Int, 66, 2202, 10.1111/j.1523-1755.2004.66010.x

Ramesh, 2005, p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice, Am J Physiol Renal Physiol, 289, F166, 10.1152/ajprenal.00401.2004

Li, 2004, PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G, Am J Physiol Renal Physiol, 287, F990, 10.1152/ajprenal.00206.2004

Wei, 2007, The pathological role of Bax in cisplatin nephrotoxicity, Kidney Int, 72, 53, 10.1038/sj.ki.5002256

Tsuruya, 2003, Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death, Kidney Int, 63, 72, 10.1046/j.1523-1755.2003.00709.x

Dursun, 2006, Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis, Am J Physiol Renal Physiol, 291, F578, 10.1152/ajprenal.00455.2005

Strasser, 2000, Apoptosis signaling, Annu Rev Biochem, 69, 217, 10.1146/annurev.biochem.69.1.217

Razzaque, 1999, Cisplatin-induced apoptosis in human proximal tubular epithelial cells is associated with the activation of the Fas/Fas ligand system, Histochem Cell Biol, 111, 359, 10.1007/s004180050368

Ramesh, 2002, TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity, J Clin Invest, 110, 835, 10.1172/JCI200215606

Ramesh, 2004, Inflammatory cytokines in acute renal failure, Kidney Int Suppl, 66, S56, 10.1111/j.1523-1755.2004.09109.x

Danial, 2004, Cell death: critical control points, Cell, 116, 205, 10.1016/S0092-8674(04)00046-7

Green, 1998, Mitochondria and apoptosis, Science, 281, 1309, 10.1126/science.281.5381.1309

Lee, 2001, Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells, Biochem Pharmacol, 62, 1013

Park, 2002, Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways, J Am Soc Nephrol, 13, 858, 10.1681/ASN.V134858

Jiang, 2004, Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity, Am J Physiol Renal Physiol, 287, F1140, 10.1152/ajprenal.00262.2004

Jiang, 2006, Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis, Oncogene, 25, 4056, 10.1038/sj.onc.1209440

Jiang, 2007, Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation, J Biol Chem, 282, 2636, 10.1074/jbc.M606928200

Nagothu, 2005, Fibrate prevents cisplatin-induced proximal tubule cell death, Kidney Int, 68, 2680, 10.1111/j.1523-1755.2005.00739.x

Seth, 2005, p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury, J Biol Chem, 280, 31230, 10.1074/jbc.M503305200

Wangila, 2006, Prevention of cisplatin-induced kidney epithelial cell apoptosis with a Cu superoxide dismutase-mimetic [copper2II(3,5-ditertiarybutylsalicylate)4(ethanol)4], Toxicol In vitro, 20, 1300, 10.1016/j.tiv.2006.04.002

Jiang, 2007, Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity, Biochem Pharmacol, 73, 1499, 10.1016/j.bcp.2007.01.010

Wang, 2004, Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria, J Biol Chem, 279, 19948, 10.1074/jbc.M313629200

Yang, 2007, Mcl-1 is downregulated in cisplatin-induced apoptosis, and proteasome inhibitors restore Mcl-1 and promote survival in renal tubular epithelial cells, Am J Physiol Renal Physiol, 292, F1710, 10.1152/ajprenal.00505.2006

Sheikh-Hamad, 2004, Cellular and molecular studies on cisplatin-induced apoptotic cell death in rat kidney, Arch Toxicol, 78, 147, 10.1007/s00204-003-0521-4

Brooks, 2007, Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins, Proc Natl Acad Sci USA, 104, 11649, 10.1073/pnas.0703976104

Boyce, 2006, Cellular response to endoplasmic reticulum stress: a matter of life or death, Cell Death Differ, 13, 363, 10.1038/sj.cdd.4401817

Liu, 2005, Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis, J Am Soc Nephrol, 16, 1985, 10.1681/ASN.2004090768

Peyrou, 2007, Cisplatin, gentamicin, and p-aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys, Toxicol Sci, 99, 346, 10.1093/toxsci/kfm152

Cummings, 2004, Role of an endoplasmic reticulum Ca2+-independent phospholipase A2 in cisplatin-induced renal cell apoptosis, J Pharmacol Exp Ther, 308, 921, 10.1124/jpet.103.060541

Cummings, 2002, Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways, J Pharmacol Exp Ther, 302, 8, 10.1124/jpet.302.1.8

Vandenabeele, 2006, Caspase inhibitors promote alternative cell death pathways, Sci STKE, 2006, pe44, 10.1126/stke.3582006pe44

Kondo, 2006, Autophagy and cancer therapy, Autophagy, 2, 85, 10.4161/auto.2.2.2463

Price, 2003, Cell cycle regulation: repair and regeneration in acute renal failure, Semin Nephrol, 23, 449, 10.1016/S0270-9295(03)00087-1

Delaval, 2007, A cell cycle hypothesis of cooperative oncogenesis (Review), Int J Oncol, 30, 1051

Bloom, 2007, Multiple levels of cyclin specificity in cell-cycle control, Nat Rev Mol Cell Biol, 8, 149, 10.1038/nrm2105

Ishikawa, 2006, DNA damage-dependent cell cycle checkpoints and genomic stability, DNA Cell Biol, 25, 406, 10.1089/dna.2006.25.406

Megyesi, 1996, The p53-independent activation of transcription of p21 WAF1/CIP1/SDI1 after acute renal failure, Am J Physiol Renal Physiol, 271, F1211, 10.1152/ajprenal.1996.271.6.F1211

Price, 2004, Protection of renal cells from cisplatin toxicity by cell cycle inhibitors, Am J Physiol Renal Physiol, 286, F378, 10.1152/ajprenal.00192.2003

Yu, 2005, Identification of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity, Am J Physiol Renal Physiol, 289, F514, 10.1152/ajprenal.00101.2005

Price, 2006, Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2, J Am Soc Nephrol, 17, 2434, 10.1681/ASN.2006020162

Yu, 2007, The involvement of the Cdk2-E2f1 pathway in cisplatin cytotoxicity in vitro and in vivo, Am J Physiol Renal Physiol, 293, F52, 10.1152/ajprenal.00119.2007

Wei, 2007, Activation and involvement of p53 in cisplatin-induced nephrotoxicity, Am J Physiol Renal Physiol, 293, F1282, 10.1152/ajprenal.00230.2007

Chipuk, 2004, Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis, Science, 303, 1010, 10.1126/science.1092734

Zhou, 2004, The induction of cell cycle regulatory and DNA repair proteins in cisplatin-induced acute renal failure, Toxicol Appl Pharmacol, 200, 111, 10.1016/j.taap.2004.04.003

Wang, 2006, Caspase-mediated cleavage of ATM during cisplatin-induced tubular cell apoptosis: inactivation of its kinase activity toward p53, Am J Physiol Renal Physiol, 291, F1300, 10.1152/ajprenal.00509.2005

Pabla N, Huang S, Mi QS et al. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem;e-pub ahead of print 27 December 2007.

Itoh, 1999, A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90, Biochem J, 343, 697, 10.1042/bj3430697

Satoh, 1994, Induction and altered localization of 90-kDa heat-shock protein in rat kidneys with cisplatin-induced acute renal failure, Ren Fail, 16, 313, 10.3109/08860229409044872

Owens, 2007, Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases, Oncogene, 26, 3203, 10.1038/sj.onc.1210412

Dhillon, 2007, MAP kinase signalling pathways in cancer, Oncogene, 26, 3279, 10.1038/sj.onc.1210421

Zhuang, 2006, A death-promoting role for extracellular signal-regulated kinase, J Pharmacol Exp Ther, 319, 991, 10.1124/jpet.106.107367

Nowak, 2002, Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells, J Biol Chem, 277, 43377, 10.1074/jbc.M206373200

Arany, 2004, Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells, Am J Physiol Renal Physiol, 287, F543, 10.1152/ajprenal.00112.2004

Kim, 2005, Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells, J Appl Toxicol, 25, 374, 10.1002/jat.1081

Jo, 2005, MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis, Kidney Int, 67, 458, 10.1111/j.1523-1755.2005.67102.x

Mishima, 2006, Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity, Free Radic Biol Med, 40, 1564, 10.1016/j.freeradbiomed.2005.12.025

Francescato, 2007, Effect of JNK inhibition on cisplatin-induced renal damage, Nephrol Dial Transplant, 22, 2138, 10.1093/ndt/gfm144

Baliga, 1999, Oxidant mechanisms in toxic acute renal failure, Drug Metab Rev, 31, 971, 10.1081/DMR-100101947

Kruidering, 1997, Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain, J Pharmacol Exp Ther, 280, 638

Davis, 2001, Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide, J Am Soc Nephrol, 12, 2683, 10.1681/ASN.V12122683

Ma, 2007, Combining cisplatin with cationized catalase decreases nephrotoxicity while improving antitumor activity, Kidney Int, 72, 1474, 10.1038/sj.ki.5002556

Baliga, 1998, Role of cytochrome P-450 as a source of catalytic iron in cisplatin-induced nephrotoxicity, Kidney Int, 54, 1562, 10.1046/j.1523-1755.1998.00161.x

Baliga, 1998, In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity, Kidney Int, 53, 394, 10.1046/j.1523-1755.1998.00767.x

Agarwal, 1995, Induction of heme oxygenase in toxic renal injury: a protective role in cisplatin nephrotoxicity in the rat, Kidney Int, 48, 1298, 10.1038/ki.1995.414

Shiraishi, 2000, Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis, Am J Physiol Renal Physiol, 278, F726, 10.1152/ajprenal.2000.278.5.F726

Schaaf, 2002, Management of oxidative stress by heme oxygenase-1 in cisplatin-induced toxicity in renal tubular cells, Free Radic Res, 36, 835, 10.1080/1071576021000005267

Agarwal, 2000, Renal response to tissue injury: lessons from heme oxygenase-1 GeneAblation and expression, J Am Soc Nephrol, 11, 965, 10.1681/ASN.V115965

Tayem, 2006, Protection against cisplatin-induced nephrotoxicity by a carbon monoxide-releasing molecule, Am J Physiol Renal Physiol, 290, F789, 10.1152/ajprenal.00363.2005

Dickey, 2005, Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels, J Pharmacol Exp Ther, 314, 1052, 10.1124/jpet.105.087601

Matsushima, 1998, The role of oxygen free radicals in cisplatin-induced acute renal failure in rats, J Lab Clin Med, 131, 518, 10.1016/S0022-2143(98)90060-9

Tsuruya, 2003, Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways, Am J Physiol Renal Physiol, 285, F208, 10.1152/ajprenal.00311.2002

Sener, 2000, The protective effect of melatonin on cisplatin nephrotoxicity, Fundam Clin Pharmacol, 14, 553, 10.1111/j.1472-8206.2000.tb00440.x

Baldew, 1989, Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats, Cancer Res, 49, 3020

Naziroglu, 2004, Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats, Toxicology, 195, 221, 10.1016/j.tox.2003.10.012

Weijl, 2004, Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study, Eur J Cancer, 40, 1713, 10.1016/j.ejca.2004.02.029

Pace, 2003, Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy, J Clin Oncol, 21, 927, 10.1200/JCO.2003.05.139

Atessahin, 2005, Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats, Toxicology, 212, 116, 10.1016/j.tox.2005.04.016

De Martinis, 2001, Effect of vitamin C supplementation against cisplatin-induced toxicity and oxidative DNA damage in rats, Pharmacol Res, 44, 317, 10.1006/phrs.2001.0860

Appenroth, 1997, Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats, Arch Toxicol, 71, 677, 10.1007/s002040050444

Shimeda, 2005, Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats, Biol Pharm Bull, 28, 1635, 10.1248/bpb.28.1635

Al-Majed, 2003, Effect of oral administration of Arabic gum on cisplatin-induced nephrotoxicity in rats, J Biochem Mol Toxicol, 17, 146, 10.1002/jbt.10072

Bonventre, 2003, Recent advances in the pathophysiology of ischemic acute renal failure, J Am Soc Nephrol, 14, 2199, 10.1097/01.ASN.0000079785.13922.F6

Devarajan, 2006, Update on mechanisms of ischemic acute kidney injury, J Am Soc Nephrol, 17, 1503, 10.1681/ASN.2006010017

Lu, 2007, The inflammatory response to ischemic acute kidney injury: a result of the ‘right stuff’ in the ‘wrong place’?, Curr Opin Nephrol Hypertens, 16, 83, 10.1097/MNH.0b013e3280403c4e

Deng, 2001, Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury, Kidney Int, 60, 2118, 10.1046/j.1523-1755.2001.00043.x

Ramesh, 2004, Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha, Kidney Int, 65, 490, 10.1111/j.1523-1755.2004.00413.x

Ramesh, 2006, Cisplatin increases TNF-alpha mRNA stability in kidney proximal tubule cells, Ren Fail, 28, 583, 10.1080/08860220600843839

Ramesh, 2007, Endotoxin and cisplatin synergistically induce renal dysfunction and cytokine production in mice, Am J Physiol Renal Physiol, 293, F325, 10.1152/ajprenal.00158.2007

Zhang, 2007, Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells, Kidney Int, 72, 37, 10.1038/sj.ki.5002242

Dong, 2007, Tumor necrosis factor-alpha in cisplatin nephrotoxicity: a homebred foe?, Kidney Int, 72, 5, 10.1038/sj.ki.5002320

Ramesh, 2007, Endotoxin and cisplatin synergistically stimulate TNF-alpha production by renal epithelial cells, Am J Physiol Renal Physiol, 292, F812, 10.1152/ajprenal.00277.2006

Liu, 2006, A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity, J Am Soc Nephrol, 17, 765, 10.1681/ASN.2005010102

Faubel, 2007, Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney, J Pharmacol Exp Ther, 322, 8, 10.1124/jpet.107.119792

Klein, 1991, Renal handling of cisplatin: interactions with organic anions and cations in the dog, Clin Invest Med, 14, 388

Townsend, 2002, Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice, J Pharmacol Exp Ther, 300, 142, 10.1124/jpet.300.1.142

Hanigan, 1996, Cisplatin nephrotoxicity: inhibition of gamma-glutamyl transpeptidase blocks the nephrotoxicity of cisplatin without reducing platinum concentrations in the kidney, Am J Obstet Gynecol, 175, 270, 10.1016/S0002-9378(96)70134-5

Sadzuka, 1994, Protection against cisplatin-induced nephrotoxicity in the rat by inducers and an inhibitor of glutathione S-transferase, Biochem Pharmacol, 48, 453, 10.1016/0006-2952(94)90274-7

Nisar, 2002, N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity, Ren Fail, 24, 529, 10.1081/JDI-120006780

Sheikh-Hamad, 1997, Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine treatment, J Am Soc Nephrol, 8, 1640, 10.1681/ASN.V8101640

Zunino, 1989, Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug, Chem Biol Interact, 70, 89, 10.1016/0009-2797(89)90065-3

Santos, 2007, Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria, Cancer Chemother Pharmacol, 61, 145, 10.1007/s00280-007-0459-y

Kim, 2005, Xanthorrhizol has a potential to attenuate the high dose cisplatin-induced nephrotoxicity in mice, Food Chem Toxicol, 43, 117, 10.1016/j.fct.2004.08.018

Mora Lde, 2003, The effects of oral glutamine on cisplatin-induced nephrotoxicity in rats, Pharmacol Res, 47, 517, 10.1016/S1043-6618(03)00040-9

Atasoyu, 2005, Investigation of the role of hyperbaric oxygen therapy in cisplatin-induced nephrotoxicity in rats, Arch Toxicol, 79, 289, 10.1007/s00204-004-0627-3

Behling, 2006, Comparative study of multiple dosage of quercetin against cisplatin-induced nephrotoxicity and oxidative stress in rat kidneys, Pharmacol Rep, 58, 526

Saad, 2000, The effect of rebamipide on cisplatin-induced nephrotoxicity in rats, Pharmacol Res, 42, 81, 10.1006/phrs.2000.0662

Li, 1994, Effect of arginine on cisplatin-induced acute renal failure in the rat, Biochem Pharmacol, 47, 2298, 10.1016/0006-2952(94)90269-0

Saleh, 2005, Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide, Basic Clin Pharmacol Toxicol, 97, 91, 10.1111/j.1742-7843.2005.pto_114.x

Li, 2005, Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF, Am J Physiol Renal Physiol, 289, F469, 10.1152/ajprenal.00038.2005

Lee, 2006, Rosiglitazone ameliorates cisplatin-induced renal injury in mice, Nephrol Dial Transplant, 21, 2096, 10.1093/ndt/gfl194

Girnun, 2007, Synergy between PPARgamma ligands and platinum-based drugs in cancer, Cancer Cell, 11, 395, 10.1016/j.ccr.2007.02.025

Capizzi, 1999, Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects, Semin Oncol, 26, 72

Fenoglio, 2002, Protective effect of procaine hydrochloride on cisplatin-induced alterations in rat kidney, Anticancer Drugs, 13, 1043, 10.1097/00001813-200211000-00008

Kohda, 2005, Serum thymic factor, FTS, attenuates cisplatin nephrotoxicity by suppressing cisplatin-induced ERK activation, Biochem Pharmacol, 70, 1408, 10.1016/j.bcp.2005.08.002